消化性潰瘍藥物市場規模、佔有率和成長分析（按藥物類型、潰瘍類型、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，消化性潰瘍藥物市場規模將達到 49.3 億美元，到 2025 年將達到 51 億美元，到 2033 年將達到 67.1 億美元，在預測期（2026-2033 年）內複合年成長率為 3.5%。

全球消化性潰瘍藥物市場正穩定成長，主要促進因素是消化性潰瘍疾病的廣泛流行，影響著全球數百萬人口。人口老化以及吸菸、酗酒等不健康生活方式的增加是關鍵促進因素。此外，醫療技術的創新和新藥製劑的研發也進一步加速了市場擴張。然而，學名藥的出現和替代治療方法的興起也帶來了挑戰。儘管存在這些障礙，但人們對早期診斷和有效治療必要性的認知不斷提高，預計將顯著增強市場動態，並促進消化性潰瘍藥物的持續發展和廣泛應用。

消化性潰瘍藥物市場促進因素

推動消化性潰瘍藥物市場成長的關鍵因素之一是全球消化性潰瘍發生率的上升。這種消化系統疾病影響大量人群，導致對有效治療方案的需求不斷成長。不良的生活習慣、壓力增加以及非類固醇消炎劑（NSAIDs）的廣泛使用等因素都與消化性潰瘍發生率的上升密切相關。由此產生的對有效藥物日益成長的需求，不僅凸顯了解決這個健康問題的重要性，也推動了整個市場的擴張，因為醫療保健機構正努力滿足患者的需求。

限制消化性潰瘍治療市場的因素

全球消化性潰瘍藥物市場面臨的一大限制因素是各種替代治療方法的存在。許多患者選擇非藥物療法，例如生活方式調整、飲食改變和自然療法，這些療法被認為對控制消化性潰瘍有效。這種替代療法的趨勢可能會降低對傳統消化性潰瘍藥物的需求。此外，長期服用這些藥物可能帶來的副作用和健康風險，可能會進一步降低患者和醫療保健提供者對藥物的依賴，最終影響市場趨勢和整個行業的成長。

消化性潰瘍治療市場趨勢

全球消化性潰瘍治療市場的一個顯著趨勢是，質子幫浦阻斷劑（PPI）作為第一線治療藥物的受歡迎程度日益提高。這項轉變主要是由於PPI相比其他療法具有更優的療效和更佳的安全性。 PPI能顯著抑制胃酸分泌，從而長期緩解症狀並促進潰瘍癒合。此外，藥物製劑的不斷改進提高了生物利用度和患者依從性，進一步增強了PPI的吸引力。預計此藥物需求的成長趨勢將顯著影響消化性潰瘍治療市場的需求趨勢。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球消化性潰瘍藥物市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• 質子幫浦阻斷劑
• H2受體拮抗劑
• 抗生素
• 其他

全球消化性潰瘍藥物市場規模（依潰瘍類型及複合年成長率分類）（2026-2033 年）

• 胃潰瘍
• 十二指腸潰瘍
• 食道潰瘍

全球消化性潰瘍藥物市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院
• 零售藥房
• 網路藥房

全球消化性潰瘍治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• AstraZeneca plc.（United Kingdom）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc.（United Kingdom）
• Sanofi SA（France）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Bristol-Myers Squibb Company（United States）
• Mylan NV（Netherlands）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Ltd.（India）
• Lupin Ltd.（India）
• Zydus Cadila（India）

結論與建議

Peptic Ulcer Drugs Market size was valued at USD 4.93 Billion in 2024 and is poised to grow from USD 5.1 Billion in 2025 to USD 6.71 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The global market for peptic ulcer drugs is experiencing consistent growth, primarily influenced by the widespread prevalence of peptic ulcer disease, which impacts millions globally. Key drivers include an aging population and a rise in unhealthy lifestyle choices, such as smoking and excessive alcohol consumption. Moreover, innovations in medical technology and the development of new drug formulations are further propelling market expansion. However, the presence of generic alternatives and the rise of alternative treatment methods present challenges. Despite these hurdles, growing awareness around the necessity of early diagnosis and efficient treatment is anticipated to significantly enhance market dynamics, fostering continued advancements and adoption of peptic ulcer medications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segments Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

A significant factor propelling the growth of the peptic ulcer drugs market is the rising incidence of peptic ulcers globally. These gastrointestinal disorders impact a vast number of individuals, resulting in an increased need for effective treatment solutions. Contributing elements, such as poor lifestyle choices, heightened stress levels, and the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs), have been linked to the escalated occurrence of peptic ulcers. Consequently, this growing demand for effective medication not only highlights the importance of addressing this health issue but also fosters overall market expansion as healthcare providers seek to meet the needs of affected patients.

Restraints in the Peptic Ulcer Drugs Market

A key limitation facing the global peptic ulcer drugs market is the presence of various alternative treatment options. Many individuals turn to non-pharmacological methods, including lifestyle changes, dietary adjustments, and natural remedies, which are viewed as effective in managing peptic ulcers. This preference for alternatives can reduce the demand for conventional peptic ulcer medications. Additionally, concerns surrounding the potential side effects and health risks linked to prolonged use of these drugs may further deter patients and healthcare providers from relying solely on pharmaceuticals, ultimately affecting market trends and overall growth within the industry.

Market Trends of the Peptic Ulcer Drugs Market

A significant trend in the global peptic ulcer drugs market is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is largely attributed to the superior efficacy and favorable safety profiles of PPIs in comparison to alternative therapies, as they significantly decrease stomach acid production, thereby offering prolonged symptom relief and aiding in ulcer healing. Furthermore, ongoing advancements in drug formulations have enhanced the bioavailability and compliance rates among patients, further solidifying the appeal of PPIs. The growing inclination toward this class of medications is poised to substantially influence demand dynamics within the peptic ulcer drugs market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2026-2033)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations